[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. reported an insider equity transaction for its SVP, Research and Development. On December 12, 2025, the officer received 67,253 restricted stock units (RSUs) of common stock at a price of $0, bringing their directly held common shares to 106,844.

On the same date, the company cancelled several employee stock options held by the officer pursuant to an option exchange, with exercise prices ranging from $5.01 to $13.47, leaving 0 derivative securities beneficially owned. The cancelled options had been scheduled to vest over multi-year periods based on continued service.

Insider Trade Summary

Net Buyer: 67,253 shares

Net Buy 6 txns

Insider Raymon Heather

Role SVP, Research and Development

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option (Right to Buy)	18,239	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	12,539	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	14,819	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	11,399	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	10,259	$0.00	--
Grant/Award	Common Stock	67,253	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 106,844 shares (Direct)

Footnotes (1)

1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. 25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter. 25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/12/2025 - 07:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raymon Heather

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		67,253(1)	A	$0(2)	106,844	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$5.14	12/12/2025		D			18,239	(3)	11/02/2030	Common Stock	18,239	(2)	0	D
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			12,539	(4)	04/02/2033	Common Stock	12,539	(2)	0	D
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			14,819	(5)	04/02/2033	Common Stock	14,819	(2)	0	D
Employee Stock Option (Right to Buy)	$5.18	12/12/2025		D			11,399	(6)	01/23/2034	Common Stock	11,399	(2)	0	D
Employee Stock Option (Right to Buy)	$13.47	12/12/2025		D			10,259	(7)	05/01/2034	Common Stock	10,259	(2)	0	D

Explanation of Responses:

1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").

2. On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.

3. 25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.

4. 25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

5. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

6. Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.

7. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Andrew Cronauer, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.